Dagens Industri SV

Orexo satsar på viktminskningstablett – har sökt patent

Orexo tar nästa steg inom nya fetmamediciner och utvecklar en oral behandling med stöd av bolagets egen Amorphox-teknologi. ”Jag tror att vi kan göra en mycket mer effektiv tablett”, säger vd Nikolaj Sørensen till Di:s nyhetstjänst Läkemedelsmarknaden.

Mar 24, 2026 &03002424202631; 18:00 UTC www.di.se Trending 2/5

Read original on www.di.se ↗

↗

Positive for markets

Sentiment score: +65/100

Moderate impact Medium-term (weeks)

WHAT THIS MEANS

Orexo announces development of oral weight-loss tablet using proprietary Amorphox technology with patent filing, positioning itself in the high-growth obesity medication market. Fresh catalyst from Swedish biotech with clear R&D advancement, but market context shows risk-off sentiment (VIX +3.59%, S&P -0.25%).

AI CONFIDENCE

62% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

OREX.ST

OREX.STStock

Expected to rise

Fresh patent filing for oral obesity treatment using proprietary technology; positive R&D catalyst in high-demand therapeutic area. However, broader market risk-off (VIX spike, S&P weakness) may limit immediate upside.

⇅

Euro Stoxx 50

^STOXX50EIndex

High volatility expected

European biotech sentiment positive but macro headwinds (VIX +3.59%) create conflicting signals; sector rotation risk.

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

OREX.ST has genuine catalyst (patent + tech advantage) but macro headwinds limit conviction. Wait for market stabilization or entry on dip if VIX normalizes. Biotech typically underperforms in risk-off; upside capped until broader sentiment improves. [MOVE:2.5%]

KEY SIGNALS

Fresh patent filing (10 min old) — not yet priced inProprietary Amorphox technology differentiationCEO confidence quote on efficacyObesity drug market tailwinds (GLP-1 class expansion)Risk-off macro backdrop (VIX +3.59%) may suppress biotech rally

SECTORS INVOLVED

BiotechnologyPharmaceuticalsHealthcare

Analysis generated on Mar 24, 2026 at 18:10 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Dagens Industri. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Orexo satsar på viktminskningstablett – har sökt patent

RELATED INTELLIGENCE